Is Egrifta (Tesamorelin) Legal in Washington State? How Women Can Access It

What Tesamorelin Is and Why Women Are Asking About It

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It tells your pituitary gland to release more growth hormone, which in turn drives down visceral adipose tissue (VAT). The FDA approved it in 2010 under the brand name Egrifta for a specific population: adults with HIV who have developed excess belly fat as a side effect of long-term antiretroviral therapy, a condition called HIV-associated lipodystrophy.

Interest among women outside that approved population has grown sharply, driven partly by online discussions about visceral fat gain during perimenopause and the declining growth hormone axis that accelerates after the final menstrual period. That is a real physiological phenomenon. Whether tesamorelin is the right tool for it is a separate, evidence-dependent question.

The legal question comes first. Patients in Washington State searching for tesamorelin sometimes encounter compounding pharmacies selling it without a named-patient prescription, or online vendors marketing it as a "research peptide." Those are two very different legal categories, and the distinction matters to your safety as much as to the law.

Is Egrifta (Tesamorelin) Legal in Washington State?

Yes. Tesamorelin is legal in Washington when prescribed by a licensed practitioner and dispensed by a licensed pharmacy. Full stop.

Federal Legal Framework

Tesamorelin is an FDA-approved new drug application (NDA) product. The FDA approved Egrifta on November 10, 2010 under NDA 022505. Because it has an approved NDA, it sits in the mainstream pharmaceutical system, not in the gray area occupied by unapproved peptides like BPC-157 or CJC-1295.

The FDA's "Bulks for Compounding" lists, which restrict which substances 503A and 503B pharmacies may compound, are relevant here. An FDA-approved drug like tesamorelin may be compounded under limited conditions, primarily when the commercially available product is on the drug shortage list or when a prescriber documents a clinical difference from the finished product. The FDA's 503A compounding framework requires a valid patient-specific prescription and a licensed prescriber-patient relationship.

Washington State Framework

Washington State pharmacy law, administered by the Washington State Department of Health and the Washington State Board of Pharmacy, requires that any prescription drug, including Egrifta, be dispensed only on a valid prescription from a practitioner licensed to prescribe in the state. Washington Revised Code 69.50 and 18.64 govern pharmacy practice and do not add any state-specific prohibition on tesamorelin beyond federal prescription requirements.

Washington does license telehealth prescribing. A licensed Washington physician, ARNP (advanced registered nurse practitioner), or physician assistant with a valid prescriber-patient relationship may prescribe Egrifta or a compounded tesamorelin formulation through a telehealth visit, provided the prescribing meets Washington's telehealth standards under RCW 70.41.

The "Research Peptide" Gray Area

Some online vendors sell tesamorelin vials labeled "for research use only, not for human use." Purchasing and self-injecting those products is a different legal situation entirely. It bypasses the prescriber relationship, the pharmacy dispensing chain, and all quality and sterility checks. It also likely violates Washington's pharmacy practice act, which prohibits obtaining prescription drugs without a valid prescription. Beyond legality, research-grade peptide purity is unverified. This is not a route WomanRx recommends.

How to Get a Legal Egrifta Prescription in Washington

Getting a legitimate tesamorelin prescription in Washington follows the same pathway as any other prescription drug.

Step 1: Find a Qualified Prescriber

You need a licensed Washington State physician, ARNP, or PA with the authority to prescribe. The most efficient route for most women is:

• An infectious disease specialist (for HIV-associated lipodystrophy, the approved indication)
• An endocrinologist or obesity medicine specialist (for off-label evaluation)
• A women's-health telehealth platform with licensed Washington prescribers

The prescriber must perform or review a clinical workup. For tesamorelin, that typically includes fasting IGF-1 levels, a metabolic panel, glucose tolerance assessment, and documentation of clinical need.

Step 2: Verify the Pharmacy

A valid Egrifta prescription can be filled at:

• A specialty pharmacy that contracts with Theratechnologies (the manufacturer), since the brand-name product often requires specialty pharmacy distribution
• A licensed 503A compounding pharmacy, if the prescriber documents clinical rationale for a compounded formulation
• A licensed 503B outsourcing facility for larger-volume or institutional supply

Ask the pharmacy for a certificate of analysis and confirm their Washington State pharmacy license before accepting any compounded product.

Step 3: Telehealth Access

Washington State's telehealth prescribing law allows a fully remote prescriber visit for most conditions. Several telehealth platforms now include licensed Washington prescribers who can evaluate women for off-label peptide prescriptions. The prescriber must still conduct a good-faith evaluation. An online questionnaire alone is not sufficient under Washington's medical practice standards.

What the Clinical Evidence Actually Shows

This section matters because the evidence base for tesamorelin differs substantially depending on the population and because women have been underrepresented in the key trials.

The Approved Indication: HIV-Associated Lipodystrophy

The two key Phase 3 trials that led to FDA approval, LIPO-AA and LIPO-AB, enrolled 816 adults with HIV-associated lipodystrophy. At the approved dose of 2 mg/day subcutaneously, tesamorelin reduced trunk fat by a mean of approximately 18% versus placebo at 26 weeks. The trials included women, but women made up a minority of the HIV-positive lipodystrophy population studied, consistent with the historical male predominance in HIV research at that time.

Off-Label Use: Visceral Adiposity Without HIV

A smaller but growing body of literature examines tesamorelin in non-HIV adults with excess visceral fat. A 2018 randomized controlled trial published in JAMA Internal Medicine found that tesamorelin 2 mg/day reduced VAT by a mean of 18.4 cm² compared to 3.4 cm² with placebo over 52 weeks in adults without HIV. Cognitive function was also a study endpoint, and secondary findings suggested improved executive function in older adults.

Women-Specific Evidence Gap

No published trial has specifically enrolled perimenopausal or postmenopausal women as the primary population for tesamorelin. The physiological rationale is real: estrogen decline after menopause reduces hepatic IGF-1 production and amplifies the age-related fall in growth hormone pulse amplitude. This creates a hormonal environment in which visceral fat preferentially accumulates, even without changes in total caloric intake. Whether tesamorelin corrects this specific perimenopausal mechanism is extrapolated from general growth hormone physiology rather than directly studied in this population. Any clinician or platform claiming definitive evidence for tesamorelin in perimenopausal weight management is overstating the data. Women deserve to hear that clearly.

A framework for thinking about off-label use in women across life stages:

| Life Stage | VAT Accumulation Risk | GH Axis Status | Tesamorelin Evidence | |---|---|---|---| | Reproductive years | Moderate (PCOS-linked) | Normal pulsatile | None in this population | | Perimenopause | High (estrogen decline) | Declining amplitude | Extrapolated only | | Post-menopause | Highest | Significantly blunted | Extrapolated only | | HIV-positive any age | High (ART-related) | Variable | Phase 3 RCT data |

Sex-Specific Physiology: How Your Hormones Interact With Tesamorelin

Estrogen and the GH-IGF-1 Axis

Estrogen has a complex and sometimes counterintuitive relationship with growth hormone. Oral estrogen (but not transdermal estrogen) reduces hepatic IGF-1 sensitivity, meaning that women taking oral estradiol or oral contraceptives may need a higher GH stimulus to achieve the same IGF-1 rise. A study in the Journal of Clinical Endocrinology and Metabolism found that women on oral estrogen required significantly higher GH doses to achieve equivalent IGF-1 responses compared to women using transdermal estrogen or men. This has a direct clinical implication: if you are taking oral HRT or oral contraceptives, your IGF-1 response to tesamorelin may be blunted, and your prescriber should account for this in monitoring.

Transdermal estradiol does not appear to impair this axis to the same degree, which is one pharmacological argument for transdermal over oral routes in perimenopausal women who are also being managed for metabolic concerns.

The Menstrual Cycle and GH Secretion

Growth hormone secretion in premenopausal women varies across the menstrual cycle, with higher pulse amplitude in the follicular phase and a relative decline in the luteal phase under progesterone dominance. This means that IGF-1 levels drawn at different cycle phases will differ, and timing your baseline labs to the early follicular phase (days 2-5) gives the most reproducible results for monitoring tesamorelin's effect.

PCOS and Visceral Adiposity

Women with polycystic ovary syndrome carry disproportionately high visceral fat burden, partly driven by insulin resistance and hyperandrogenism rather than by GH axis dysfunction. Tesamorelin targets the GH-IGF-1 axis, not insulin signaling directly. There is no published trial of tesamorelin in women with PCOS. Prescribers considering off-label use in this population should document the rationale carefully and pair it with evidence-based PCOS management, including metformin or inositol where indicated.

Pregnancy and Lactation: What Every Woman Must Know

Tesamorelin is contraindicated in pregnancy. If you are pregnant or planning to become pregnant, you must not use tesamorelin.

Pregnancy Safety

Tesamorelin is classified as FDA Pregnancy Category X. Category X drugs have demonstrated fetal risk that outweighs any possible benefit. Animal studies showed embryolethality and skeletal malformations at doses producing exposures similar to human therapeutic doses. Human pregnancy data are absent because the drug is contraindicated and trials excluded pregnant women.

If you are of reproductive age and your prescriber is considering tesamorelin, you must use reliable contraception throughout the treatment period. The FDA prescribing information states that tesamorelin should be discontinued if pregnancy is confirmed. Any woman on tesamorelin who misses a menstrual period should take a pregnancy test immediately and stop the drug pending the result.

The prescribing information recommends that women of childbearing potential use effective contraception. Reliable options include combined hormonal contraception, progestin-only methods, an intrauterine device, or barrier methods used consistently. Given tesamorelin's effect on the GH-IGF-1 axis, there is also a theoretical interaction with insulin sensitivity that could alter the pharmacodynamics of any hormonal method, though no direct interaction data exist.

Lactation

The transfer of tesamorelin into human breast milk has not been studied. The FDA prescribing information advises that breastfeeding should be discontinued if tesamorelin is required, given the unknown risk to the nursing infant and the availability of alternative approaches for most clinical scenarios outside of HIV lipodystrophy. Tesamorelin stimulates IGF-1, and IGF-1 does appear in breast milk naturally, but whether exogenous elevation through tesamorelin would meaningfully alter breast milk IGF-1 concentrations or affect infant growth is simply not known. In the absence of safety data, the conservative clinical recommendation is to avoid tesamorelin while breastfeeding.

Trying to Conceive

If you are actively trying to conceive, tesamorelin should be stopped before you start trying. There is no established washout period in the prescribing information because the drug should not be used in this situation at all. Discuss with your prescriber a minimum of one completed menstrual cycle off the drug before attempting conception, though this is clinical consensus rather than a studied interval.

Who This Treatment May Be Right For, and Who It Is Not

Potentially Appropriate Candidates

• Women with documented HIV-associated lipodystrophy on stable antiretroviral therapy, where tesamorelin has the strongest evidence base
• Women with non-HIV visceral adiposity where other interventions have been optimized and an endocrinologist has documented GH axis evaluation
• Postmenopausal women with elevated fasting IGF-1 deficiency confirmed on appropriate testing, managed by an experienced endocrinologist

Not Appropriate Candidates

• Pregnant women or those trying to conceive (contraindicated)
• Breastfeeding women (avoid; unknown transfer)
• Women with active malignancy or a history of malignancy, since tesamorelin raises IGF-1 and IGF-1 receptors are expressed on many tumor types
• Women with known hypersensitivity to tesamorelin or mannitol (the excipient)
• Women with untreated hypothyroidism or other pituitary hormone deficiencies, as these conditions impair the GH response and must be corrected first
• Women with poorly controlled diabetes: tesamorelin causes a dose-dependent increase in fasting glucose and raises HbA1c by approximately 0.24 percentage points relative to placebo, which requires careful monitoring

Side Effects Women Should Know About

Tesamorelin's side effect profile has some features that are especially relevant to women.

Fluid Retention and Joint Pain

Growth hormone stimulation promotes sodium retention and can cause peripheral edema, arthralgia, and carpal tunnel syndrome. Women with premenstrual fluid retention or a history of carpal tunnel syndrome during pregnancy may be more sensitive to these effects in the early weeks of treatment. Most fluid retention resolves within the first month as the body adjusts.

Glucose and Insulin Effects

Tesamorelin raises fasting glucose and impairs insulin sensitivity in a dose-dependent manner. In the LIPO-AA/LIPO-AB trials, diabetes incidence was 4.7% with tesamorelin versus 2.1% with placebo over 26 weeks. Women with PCOS, a prior history of gestational diabetes, or prediabetes are at elevated baseline risk and require glucose monitoring every 8-12 weeks during treatment.

Injection Site Reactions

Subcutaneous injection site reactions, including erythema, pruritus, and pain, occur in approximately 7% of users. Rotating injection sites across the abdomen and allowing the reconstituted drug to reach room temperature before injection reduces local reactions.

Anti-Drug Antibodies

Up to 49% of patients develop anti-tesamorelin antibodies by 52 weeks. Most antibodies are non-neutralizing and do not reduce clinical effect, but a subset of patients develop neutralizing antibodies that blunt the IGF-1 response. Your prescriber should check IGF-1 levels at 3-6 month intervals to confirm you are responding.

Monitoring Schedule for Washington Women on Tesamorelin

A reasonable monitoring plan, drawn from the prescribing information and clinical endocrinology practice:

• Baseline: Fasting glucose, HbA1c, IGF-1 (early follicular phase for premenopausal women), fasting lipid panel, thyroid-stimulating hormone, pregnancy test if reproductive age
• Week 12: IGF-1, fasting glucose, clinical assessment of edema and joint symptoms
• Week 26: Full metabolic panel, IGF-1, HbA1c, clinical reassessment of VAT (waist circumference, and ideally repeat DXA or CT if available)
• Every 6 months ongoing: IGF-1, fasting glucose, HbA1c, pregnancy test if reproductive age and not using permanent contraception

IGF-1 should be kept within the age- and sex-specific normal range. Targeting the upper third of normal range and not above the upper limit of normal is a reasonable clinical goal and reduces the theoretical risk of IGF-1-driven mitogenic effects.